Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 0 (Enzyme Inhibitors). Found 3 abstracts

Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium.[see comment]. Cell. 2007 Jun 29;129(7):1351-63.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 0 (Enzyme Inhibitors)

0 (Enzyme Inhibitors) Enzyme Inhibitors ai [Antagonists & Inhibitors] Protein-Serine-Threonine Kinases Non-US Gov't Support de [Drug Effects] me [Metabolism] Phosphorylation 15663-27-1 (Cisplatin) EC 2-7-1-37 (Protein-Serine-Threonine Kinases) Human pd [Pharmacology] Cisplatin dt [Drug Therapy] Deoxycytidine 100286-90-6 (irinotecan) Vindesine ph [Physiology] Use] Non-Small-Cell Lung Carcinoma Phytogenic) 0 (Antineoplastic Agents tu [Therapeutic Use] Adjuvant Radiotherapy Cilia Type I) EC 5-99-1-2 (DNA Topoisomerases Antineoplastic Combined Chemotherapy Protocols Proto-Oncogene Proteins Signal Transducing) 0 (Adaptor Proteins Taxoids Lung Neoplasms 951-77-9 (Deoxycytidine) 53123-88-9 (Sirolimus) 0 (Antineoplastic Combined Chemotherapy Protocols) 154447-36-6 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) 53643-48-4 (Vindesine) Signal Transducing Adaptor Proteins Small Cell Carcinoma pa [Pathology] 0 (Taxoids) Enzyme Activation Morpholines human) 0 (NEDD9 protein EC 2-7-1-37 (Protein Kinases) 0 (Morpholines) 0 (Proto-Oncogene Proteins) Phosphoproteins EC 3-5-1 (Histone Deacetylases) 0 (Phosphoproteins) 33419-42-0 (Etoposide) Sirolimus Mitosis ul [Ultrastructure] US Gov't Support-PHS EC 1-17-4 (Ribonucleotide Reductases) Comparative Study Cell Division EC 2-7-1 (mTOR protein) ge [Genetics] 103882-84-4 (gemcitabine) tu [Therapeutic 1-Phosphatidylinositol 3-Kinase Female Antineoplastic Antimetabolites Protein Kinases ad [Administration & Dosage] Camptothecin EC 2-7-1-37 (proto-oncogene protein akt) Cultured Tumor Cells Phytogenic Antineoplastic Agents 7689-03-4 (Camptothecin) North America Antineoplastic Agents Ribonucleotide Reductases Apoptosis Ovarian Neoplasms Chromones EC 2-7-1 (aurora kinase) Antineoplastic) 0 (Antimetabolites Histone Deacetylases human) EC 3-5-1 (HDAC6 protein aa [Analogs & Derivatives] Molecular Models Signal Transduction 0 (Antineoplastic Agents) EC 2-7-1-137 (1-Phosphatidylinositol 3-Kinase) 0 (Chromones) Etoposide Cell Line Type I DNA Topoisomerases Survival Rate
Last updated on Wednesday, March 04, 2020